Research programme: EP4 receptor modulators - Ariel PharmaceuticalsAlternative Names: EP4 receptor agonists - Ariel Pharmaceuticals; EP4 receptor antagonists - Ariel Pharmaceuticals; Prostanoid EP4 receptor ligands - Ariel Pharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator Ariel Pharmaceuticals
- Mechanism of Action Prostaglandin E EP4 receptor antagonists; Prostaglandin E EP4 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation; Migraine
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Migraine in USA
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in USA
- 23 Sep 2011 Early research in Inflammation in USA (unspecified route)